NCT05387785View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

ANG-3070

Orally administered tyrosine kinase inhibitor capsule.

DRUG

Placebo

Orally administered placebo capsule

Sponsors
All Listed Sponsors
lead

Angion Biomedica Corp

INDUSTRY

NCT05387785 - Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter